Kidney failure was defined as an increase of serum creatinine > 2

Kidney failure was defined as an increase of serum creatinine > 2 mg/dl or requirement of renal replacement therapy. Factors

considered for univariate analysis for Predisposition included patient demographics, severity and etiology of underlying liver disease, baseline biochemical parameters, presence of ascites,comorbidities including chronic kidney disease; for Injury- diuretic use, nephrotoxicity, bacterial infections, variceal bleed; for Response-components of systemic inflammatory response syndrome and for Organ failure-extrarenal organ failures i.e. cerebral, circulatory and respiratory defined according to CLIF-SOFA score. Results: Of 1365 patients with ACLF (age 44 ±12.9 years, 83% males) with MELD selleck kinase inhibitor score of 32.6 ± 9.4, 29% developed kidney

failure. Factors significant (p,OR, 95% CI) on multivariate analysis for P component were high baseline MELD (&30) (<0.001, 1.72, 1.34-2.2) and low serum sodium (<130mEq/l) (0.002, 1.4, 1.14-1.9); for I component, bacterial infections (0.02, 1.4, 1.04-1.96); for R component, leucocytosis (0.03, 1.3, 1.021.71); for O component, circulatory failure (<0.0001, 4.6, 3.2-6.7) and cerebral failure (<0.001,2.7, 2.1-3.6). The combination of these four components into a single-value predictor of kidney failure in the combined PIRO model identified circulatory failure (OR 5.8, 95% CI 3.1-11.1) and cerebral failure (OR 2.1, 95% CI 1.2-3.7) as the most significant predictors. Amongst all organ failures, presence of circulatory failure at baseline was

the most see more significant predictor of mortality find more (OR 1.8, 95% CI 1.1-3.3). Conclusions: The PIRO model could be a novel approach to identify and stratify ACLF patients at risk of kidney failure. Kidney failure is commonly associated with presence of extra-renal organ failures at baseline amongst which circulatory failure predicts mortality independent of both renal and other organ failures. Disclosures: George K. Lau – Consulting: Roche, Novartis, Roche, Novartis, Roche, Novartis, Roche, Novartis Qin Ning – Advisory Committees or Review Panels: ROCHE, NOVARTIS, BMS, MSD, GSK; Consulting: ROCHE, NOVARTIS, BMS, MSD, GSK; Grant/Research Support: ROCHE, NOVARTIS, BMS; Speaking and Teaching: ROCHE, NOVAR-TIS, BMS, MSD, GSK Diana A. Payawal – Advisory Committees or Review Panels: United Laboratories; Consulting: Takeda Pharmaceutical; Speaking and Teaching: Fatima Medical University Hospital Soek Siam Tan – Advisory Committees or Review Panels: Abbvie Osamu Yokosuka – Grant/Research Support: Chugai, Taiho, Bristol Myers The following people have nothing to disclose: Rakhi Maiwall, Shiv K. Sarin, Chandan K. Kedarisetty, Richard Moreau, Suman Kumar, Zaigham Abbas, Deepak N.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>